Table 2b.
Prevalence of chronic health conditions of survivors of Ewing sarcoma (EWS) (N=90) and community controls (N=272).
| Cardiomyopathy | Hypertension | Myocardial infarction | Hypercholesterolemia | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Cardiovascular | Normal | 84 | (93.3) | 270 | (99.3) | 0.004 | 42 | (46.7) | 153 | (56.3) | 0.11 | 90 | (100) | 269 | (98.9) | 1.0 | 57 | (63.3) | 191 | (70.2) | 0.22 | |||
| Grade 1 | 0 | (0) | 0 | (0) | 36 | (40.0) | 79 | (29.0) | 0 | (0) | 2 | (0.7) | 29 | (32.2) | 64 | (23.5) | ||||||||
| Grade 2 | 3 | (3.3) | 1 | (0.3) | 11 | (12.2) | 31 | (11.4) | 0 | (0) | 0 | (0) | 4 | (4.4) | 17 | (6.3) | ||||||||
| Grade 3 | 3 | (3.3) | 1 | (0.3) | 1 | (1.1) | 9 | (3.3) | 0 | (0) | 1 | (0.3) | 0 | (0) | 0 | (0) | ||||||||
| Grade 4 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||
| Hypertriglyceridemia | Peripheral Motor Neuropathy | Peripheral Sensory Neuropathy | Chronic Kidney Disease | |||||||||||||||||||||
| EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Normal | 76 | (84.4) | 272 | (100) | 0.24 | Neurologic | 76 | (84.4) | 272 | (100) | <0.001 | 55 | (61.1) | 237 | (87.1) | <0.001 | Renal | 87 | (96.7) | 269 | (98.9) | 0.17 | ||
| Grade 1 | 8 | (8.9) | 0 | (0) | 8 | (8.9) | 0 | (0) | 29 | (32.2) | 30 | (11) | 1 | (1.1) | 0 | (0) | ||||||||
| Grade 2 | 6 | (6.7) | 0 | (0) | 6 | (6.7) | 0 | (0) | 4 | (4.4) | 5 | (1.8) | 2 | (2.2) | 3 | (1.1) | ||||||||
| Grade 3 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (2.2) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||
| Grade 4 | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||
| Decreased Bone Mineral Density | Scoliosis | Prosthetic Malfunction‡ | ||||||||||||||||||||||
| EWS Survivors | Controls† | EWS Survivors | Controls | EWS Survivors | Controls | |||||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | ||||||||||
| Normal | 55 | (61.1) | -- | 67 | (74.4) | 271 | (99.6) | <0.001 | 8 | (66.7) | -- | -- | -- | |||||||||||
| Grade 1 | 30 | (33.3) | -- | -- | 14 | (15.6) | 1 | (0.3) | 0 | (0) | -- | -- | ||||||||||||
| Grade 2 | 5 | (5.6) | -- | -- | 5 | (5.6) | 0 | (0) | 0 | (0) | -- | -- | ||||||||||||
| Grade 3 | 0 | (0) | -- | -- | 4 | (4.4) | 0 | (0) | 4 | (33.3) | -- | -- | ||||||||||||
| Grade 4 | 0 | (0) | -- | -- | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | ||||||||||||
| Abnormal FEV1 | Abnormal TLC | Abnormal DLCOcorr | ||||||||||||||||||||||
| EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | |||||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | ||||||||||
| Normal | 72 | (80.0) | 252 | (92.6) | 0.001 | 77 | (85.6) | 265 | (97.4) | <0.001 | 71 | (78.9) | 259 | (95.2) | <0.001 | |||||||||
| Grade 1 | 8 | (8.9) | 12 | (4.4) | 4 | (4.4) | 6 | (2.2) | 0 | (0) | 12 | (4.4) | ||||||||||||
| Grade 2 | 6 | (6.7) | 5 | (1.8) | 6 | (6.7) | 1 | (0.3) | 18 | (20.0) | 1 | (0.3) | ||||||||||||
| Grade 3 | 3 | (3.3) | 3 | (1.1) | 3 | (3.3) | 0 | (0) | 1 | (1.1) | 0 | (0) | ||||||||||||
| Grade 4 | 1 | (1.1) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | ||||||||||||
| Abnormal Fasting Glucose | Overweight/Obesity | Sex Hormone Insufficiency* | Oligospermia/Azoospermia** | |||||||||||||||||||||
| EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls | EWS Survivors | Controls† | |||||||||||||||||
| N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | N | (%) | N | (%) | (p) | |||||
| Normal | 68 | (75.6) | 218 | (80.1) | 0.35 | 33 | (36.7) | 100 | (36.8) | 0.99 | 66 | (80.5) | 232 | (96.7) | <0.001 | 4 | (10.5) | -- | -- | -- | ||||
| Grade 1 | 14 | (15.6) | 43 | (15.8) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | ||||||||
| Grade 2 | 2 | (2.2) | 10 | (3.7) | 28 | (31.1) | 69 | (25.4) | 9 | (11.0) | 0 | (0) | 11 | (28.9) | -- | -- | ||||||||
| Grade 3 | 5 | (5.6) | 1 | (0.3) | 24 | (26.7) | 78 | (28.7) | 7 | (8.5) | 8 | (3.3) | 23 | (60.5) | -- | -- | ||||||||
| Grade 4 | 1 | (1.1) | 0 | (0) | 5 | (5.6) | 25 | (9.2) | 0 | (0) | 0 | (0) | 0 | (0) | -- | -- | ||||||||
FEV1: forced expiratory volume in one second; TLC: total lung capacity; DLCOcorr: diffusion capacity of lungs for carbon monoxide corrected for hemoglobin
†
Not assessed among controls
‡
Assessed among survivors with primary limb-sparing surgery (n=12)
*
Assessed among evaluable survivors (n=82) and controls (n=240); women above age of 40 years or actively receiving hormonal therapy were considered inevaluable
**
Assessed among male survivors who consented to semen analysis (n=38)